Niagen Bioscience, Inc.

Niagen Bioscience, Inc. is a global bioscience company focused on promoting healthy aging. The company's team, including world-renowned scientists, conducts pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism and is present in every cell of the human body. NAD+ levels naturally decline with age, by up to 65% between ages 30 and 70, and can also be impacted by poor diet, excess alcohol consumption, and certain disease states. Niagen Bioscience is at the forefront of developing and commercializing effective methods to support NAD+ levels and promote healthy aging. The company's strategic shift to become a global bioscience company dedicated to healthy aging began with the acquisition of Healthspan Research LLC on March 12, 2017, which offered Tru Niagen® branded products. Healthspan Research LLC was dissolved on January 15, 2021, with its assets and liabilities contributed to ChromaDex, Inc., a wholly owned subsidiary of ChromaDex Corporation. The company was originally incorporated as Cody Resources, Inc. on May 21, 2008, and changed its name to ChromaDex Corporation on June 20, 2008. It became listed on the Nasdaq Capital Market on April 25, 2016. Effective March 19, 2025, the company changed its name to "Niagen Bioscience, Inc." and its Nasdaq ticker symbol to "NAGE".